drugset / Trial / NCT01497431

Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants

NCT01497431

Phase 1 Completed 66 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupDouble-blindPrevention

Summary

This randomized phase I trial studies the side effects and the best dose of Se-methyl-seleno-L-cysteine or selenomethionine in preventing prostate cancer in healthy participants. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of Se-methyl-seleno-L-cysteine or selenomethionine, two different types of selenium compounds, may prevent prostate cancer from forming.

Timeline

Start
2011-11
Primary completion
2014-06
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylselenocysteine Other / unclassified Oral

Indications